Claims for Patent: 6,087,555

Summary for Patent: 6,087,555

Title:	Mice lacking expression of osteoprotegerin
Abstract:	Disclosed is a mouse in which expression of the gene encoding Osteoprotegerin is suppressed. Also disclosed is a nucleic acid construct useful in preparing such a mouse, and a cell line containing such construct.
Inventor(s):	Dunstan; Colin (Newbury Park, CA), Simonet; Scott (Thousand Oaks, CA), Sarosi; Ildiko (Newbury Park, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	08/943,687
Patent Claims:	1. A transgenic mouse whose genome comprises a disruption of the endogenous osteoprotegerin (OPG) gene, wherein said disruption comprises the insertion of a selectable marker sequence, and wherein said disruption results in said mouse exhibiting decreased bone density as compared to a wild-type mouse. 2. The transgenic mouse of claim 1, wherein said disruption is a homozygous disruption. 3. The transgenic mouse of claim 2, wherein said homozygous disruption results in a null mutation of the endogenous gene encoding osteoprotegerin (OPG). 4. An isolated nucleic acid comprising an osteoprotegerin (OPG) knockout construct comprising a selectable marker sequence flanked by DNA sequences homologous to the endogenous OPG gene, wherein when said construct is introduced into a mouse or an ancestor of said mouse at an embryonic stage, said selectable marker sequence disrupts the endogenous OPG gene in the genome of said mouse such that said mouse exhibits decreased bone density as compared to a wild type mouse. 5. A vector comprising the nucleic acid of claim 4. 6. A mouse RW4 embryonic stem cell line comprising the osteoprotegerin (OPG) knockout construct of claim 4. 7. A method of screening compounds that modulate bone resorption comprising introducing a compound into the mouse of claim 1 and determining the increase or decrease in bone resorption of said mouse as compared to the bone resorption of said mouse prior to the administration of the compound. 8. The osteoprotegerin (OPG) knockout construct according to claim 4, wherein said construct comprises from 5' to 3', the OPG genomic fragment 3 which is a XmnI/XmnI subfragment of a portion of exon 1 and most of exon 2, the neo cassette, OPG genomic fragment 2 which is an EcoRI/EcoRI fragment of the 3' portion of exon 2, intron 2, extron 3, and most of intron 3, and the thymidine kinase cassette.

Details for Patent 6,087,555

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26